Performance of gene-expression profiling test score variability to predict future clinical events in heart transplant recipients

Abstract excerpt

BACKGROUND: A single non-invasive gene expression profiling (GEP) test (AlloMap®) is often used to discriminate if a heart transplant recipient is at a low risk of acute cellular rejection at time of testing. In a randomized trial, use of the test (a GEP score from 0-40) has been shown to be non-inferior to a routine endomyocardial biopsy for surveillance after heart transplantation in selected low-risk patients...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Valve Diseases and Treatments
• Share to Renal Transplantation Outcomes and Treatments
• Share to Transplantation: Methods and Outcomes